Insider Trading Alert - UNM, SEM And BMY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 13, 2014, 133 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $83.06 to $209,607,265.20.

Highlighted Stocks Traded by Insiders:

Unum Group (UNM) - FREE Research Report

Bishop III E. Liston who is EVP & General Counsel at Unum Group sold 668 shares at $36.07 on March 13, 2014. Following this transaction, the EVP & General Counsel owned 88,080 shares meaning that the stake was reduced by 0.75% with the 668-share transaction.

The shares most recently traded at $36.00, down $0.07, or 0.19% since the insider transaction. Historical insider transactions for Unum Group go as follows:

  • 4-Week # shares sold: 32,188
  • 12-Week # shares sold: 97,288
  • 24-Week # shares sold: 158,279

The average volume for Unum Group has been 1.5 million shares per day over the past 30 days. Unum Group has a market cap of $9.3 billion and is part of the financial sector and insurance industry. Shares are up 2.39% year-to-date as of the close of trading on Friday.

Unum Group, together with its subsidiaries, provides group and individual disability insurance products primarily in the United States and the United Kingdom. The stock currently has a dividend yield of 1.63%. The company has a P/E ratio of 11.0. Currently there are 3 analysts that rate Unum Group a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UNM - FREE

TheStreet Quant Ratings rates Unum Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Unum Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Select Medical Holdings Corporation (SEM) - FREE Research Report

Welsh Carson Anderson & Stowe Ix Lp who is 10% Owner at Select Medical Holdings Corporation sold 19.1 million shares at $10.95 on March 13, 2014. Following this transaction, the 10% Owner owned 7.4 million shares meaning that the stake was reduced by 72.08% with the 19.1 million-share transaction.

WCAS Capital Partners IV, L.P. who is 10% Owner at Select Medical Holdings Corporation sold 857,784 shares at $10.95 on March 13, 2014. Following this transaction, the 10% Owner owned 332,212 shares meaning that the stake was reduced by 72.08% with the 857,784-share transaction.

The shares most recently traded at $11.69, up $0.74, or 6.33% since the insider transaction. Historical insider transactions for Select Medical Holdings Corporation go as follows:

  • 4-Week # shares sold: 115,970
  • 12-Week # shares sold: 11.4 million
  • 24-Week # shares sold: 21.2 million

The average volume for Select Medical Holdings Corporation has been 1.1 million shares per day over the past 30 days. Select Medical Holdings Corporation has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are up 1.46% year-to-date as of the close of trading on Friday.

Select Medical Holdings Corporation, through its subsidiary, Select Medical Corporation, operates specialty hospitals and outpatient rehabilitation clinics in the United States. It operates in two segments, Specialty Hospitals and Outpatient Rehabilitation. The stock currently has a dividend yield of 3.32%. The company has a P/E ratio of 14.7. Currently there are 2 analysts that rate Select Medical Holdings Corporation a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SEM - FREE

TheStreet Quant Ratings rates Select Medical Holdings Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and attractive valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Select Medical Holdings Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Bristol-Myers Squibb Company (BMY) - FREE Research Report

Caldarella Joseph C who is SVP & Controller at Bristol-Myers Squibb Company sold 9,137 shares at $55.20 on March 13, 2014. Following this transaction, the SVP & Controller owned 68,965 shares meaning that the stake was reduced by 11.7% with the 9,137-share transaction.

The shares most recently traded at $56.13, up $0.93, or 1.66% since the insider transaction. Historical insider transactions for Bristol-Myers Squibb Company go as follows:

  • 4-Week # shares sold: 212,641
  • 12-Week # shares sold: 331,318
  • 24-Week # shares sold: 331,318

The average volume for Bristol-Myers Squibb Company has been 8.7 million shares per day over the past 30 days. Bristol-Myers Squibb Company has a market cap of $91.7 billion and is part of the health care sector and drugs industry. Shares are up 4.53% year-to-date as of the close of trading on Friday.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The stock currently has a dividend yield of 2.59%. The company has a P/E ratio of 36.1. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMY - FREE

TheStreet Quant Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet